Overall, these results suggest that patients within the adjuvant setting with cMMR Stage III CRC should not only be routinely tested for BRAF mutations, but should also be further tested for phosphorylation of ERK and p38MAPK to fully stratify their prognosis. This evidence concerns the gene BRAF and colorectal carcinoma.